8-K: Medtronic Exceeds Q3 Expectations with Strong Revenue Growth

Medtronic plc reported robust third quarter fiscal 2026 results, surpassing revenue and non-GAAP EPS guidance, driven by strong cardiovascular performance and strategic product clearances.

Summary

• Medtronic plc announced third quarter fiscal year 2026 revenue of $9.017 billion, an increase of 8.7% as reported and 6.0% on an organic basis, exceeding Q3 guidance by 50 basis points.
• Non-GAAP diluted EPS reached $1.36, three cents ahead of the Q3 guidance mid-point, while GAAP diluted EPS was $0.89.
• The Cardiovascular Portfolio led growth with a 10.6% organic increase, notably Cardiac Ablation Solutions revenue surged 80% globally and 137% in the U.S. due to its pulsed field ablation (PFA) portfolio.
• The company secured CE Mark for Sphere-360 and initiated its U.S. pivotal trial, along with U.S. FDA clearances for Hugo robotic-assisted surgery and Stealth AXiS Surgical System for spinal procedures.
• Diabetes business revenue increased 8.3% organically, driven by double-digit growth in International markets.
• Medtronic reiterated its full fiscal year 2026 organic revenue growth guidance of approximately 5.5% and diluted non-GAAP EPS guidance of $5.62 to $5.66.
• Two key M&A transactions were executed in the quarter: CathWorks in Coronary and Renal Denervation, and Anteris in Structural Heart.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, with Medtronic exceeding its own guidance for both revenue and non-GAAP EPS, driven by robust segment performance and strategic product advancements, reinforcing confidence in its full-year outlook.

Positives

• Achieved the highest enterprise revenue growth in 10 quarters, with 6.0% organic growth, 50 basis points ahead of Q3 guidance.
• Non-GAAP diluted EPS of $1.36 was three cents ahead of the Q3 guidance mid-point.
• Cardiovascular Portfolio revenue increased 10.6% organically, with Cardiac Rhythm & Heart Failure up high-teens and Cardiac Ablation Solutions growing 80% globally (137% in the U.S.).
• Secured CE Mark for Sphere-360 and commenced its U.S. pivotal trial, expanding market access and innovation pipeline.
• Received U.S. FDA clearance for Hugo robotic-assisted surgery, with first cases already completed, and for Stealth AXiS Surgical System for spinal procedures.
• Diabetes business showed strong organic growth of 8.3%, particularly in International markets.
• Successfully executed two strategic M&A transactions with CathWorks and Anteris, strengthening key portfolios.
• Reiterated full fiscal year 2026 organic revenue growth and non-GAAP EPS guidance, indicating confidence in sustained performance.

Negatives

• GAAP diluted EPS decreased to $0.89 from $1.01 in the prior year quarter.
• Non-GAAP diluted EPS slightly decreased to $1.36 from $1.39 in the prior year quarter.
• Specialty Therapies segment reported flat organic revenue growth (-0.2%).
• Structural Heart & Aortic segment showed low-single digit organic growth (+2.6%).
• U.S. Structural Heart & Aortic revenue decreased by 1.4% in Q3 FY26.
• U.S. Specialty Therapies revenue decreased by 4.0% in Q3 FY26.
• U.S. Surgical & Endoscopy revenue decreased by 0.4% for the nine months ended January 23, 2026.

Risks

• Competitive factors in the medical device industry.
• Difficulties and delays inherent in the development, manufacturing, marketing, and sale of medical products.
• Government regulation and changing global trade policies.
• Geopolitical conflicts and general economic conditions.
• Risks associated with material acquisition and divestiture transactions.
• Potential impact from tariffs of approximately $185 million on FY26 diluted non-GAAP EPS.

Future Outlook

Medtronic reiterates its full fiscal year 2026 guidance, projecting approximately 5.5% organic revenue growth and diluted non-GAAP EPS between $5.62 and $5.66. This guidance includes a potential impact from tariffs of approximately $185 million, which, if excluded, represents an approximate 4.5% diluted non-GAAP EPS growth.

Management Comments

• Geoff Martha, Medtronic chairman and chief executive officer, stated: "Q3 marks another strong quarter, delivering 6% organic revenue growth, ahead of guidance, demonstrating the strength of our portfolio. By unlocking new markets and investing in high-growth opportunities, we are accelerating performance across the company. Our innovation pipeline and portfolio breadth give us confidence in our ability to sustain long-term growth. It's an exciting time for Medtronic."
• Thierry Piton, Medtronic chief financial officer, commented: "This quarter, we again delivered accelerated growth while investing decisively in our future. We continued to invest in R&D to strengthen our innovation pipeline, funded significant growth opportunities while driving G&A leverage, and we executed on our M&A and venture strategy with two key transactions in the quarter. Bottom line, we are executing on our roadmap and positioning the business for sustainable growth."

Industry Context

StockSavvy.ai notes that Medtronic's strong Q3 performance, particularly in cardiovascular and robotic-assisted surgery, positions it favorably within the competitive healthcare technology sector. The significant growth in pulsed field ablation (PFA) and the successful FDA clearances for Hugo robotic surgery and Stealth AXiS Surgical System demonstrate Medtronic's commitment to innovation and market leadership, potentially outpacing competitors in these high-growth segments. The strategic M&A activities also reflect a broader industry trend of consolidation and targeted acquisitions to enhance specialized portfolios.

Comparison to Industry Standards

• Medtronic's 6.0% organic revenue growth, exceeding guidance, suggests strong execution relative to many large-cap medical device companies that often face more moderate growth rates.
• The 80% growth in Cardiac Ablation Solutions, particularly 137% in the U.S., highlights Medtronic's leadership in the rapidly expanding pulsed field ablation market, potentially outperforming competitors like Boston Scientific and Johnson & Johnson in this specific segment.
• The FDA clearance for Hugo robotic-assisted surgery positions Medtronic to compete more directly with established players like Intuitive Surgical (da Vinci system) and Johnson & Johnson (Ottava system) in the growing robotic surgery market, indicating a strong push into a high-value segment.
• The reiteration of FY26 guidance, despite potential tariff impacts, suggests a stable outlook compared to some industry peers facing more volatile macroeconomic conditions.

Legal Proceedings

• The company incurred certain litigation charges, net, of $62 million for Q3 FY26 and $89 million for the nine months ended January 23, 2026.
• Adjustments were made to the company's Italian payback accruals resulting from two July 22, 2024 rulings by the Constitutional Court and a Legislative Decree published by the Italian government on June 30, 2025, for certain prior years since 2015.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance exceeding guidance, strategic acquisitions, and a robust innovation pipeline, which could lead to increased shareholder value.
• Customers/Patients: Benefit from expanded treatment options and advanced medical technologies through new product clearances like Hugo robotic-assisted surgery, Stealth AXiS Surgical System, and the CE Mark for Sphere-360.
• Employees: Potential impact from restructuring charges, which primarily relate to employee termination benefits, facility-related costs, and asset write-offs.
• Creditors: Strong operating cash flow and reiterated financial guidance suggest continued financial stability and ability to meet obligations.

Next Steps

• Continue the U.S. pivotal trial for Sphere-360.
• Further integrate and leverage the recent acquisitions of CathWorks and Anteris.
• Execute on the company's roadmap to position the business for sustainable long-term growth.
• Host a video webcast on February 17, 2026, to discuss business information for investors, analysts, and news media.

Key Dates

Recommendation

Medtronic's Q3 FY26 results demonstrate strong operational execution, exceeding both revenue and non-GAAP EPS guidance. The robust performance in key growth areas like Cardiovascular, particularly Cardiac Ablation Solutions, and strategic advancements in robotic surgery with Hugo FDA clearance, signal a healthy innovation pipeline and market expansion. The reiteration of full-year guidance, despite potential tariff headwinds, provides confidence in future performance. These factors, combined with strategic M&A, suggest a positive trajectory for the company, making it an attractive investment.

Keywords

Medtronic, MDT, Healthcare Technology, Medical Devices, Q3 Earnings, Financial Results, Cardiovascular, Cardiac Ablation, Pulsed Field Ablation, Robotic Surgery, Hugo, Stealth AXiS, Diabetes, Neuroscience, M&A, FDA Clearance, CE Mark